In short thesis conversations Tice BCG is just the same as all other forms just like all DCs are the same. Only those having no clue about variations being able to be better or worse at achieving desired activation would buy that false assertion. Longs know specificity matters for DCs, component activation and maturation sources. The up and comer producer of BCG from California that suggests they have a more immune response potentiating BCG product ready to be produced commercially in the next 2 years also knows this. NWBO is working different angles and seeking multiple ways to activate DCs and source component supplies. This is otherwise known as developing workarounds to product and supply needs. Good business move. Best wishes.
Market Data 
Markets 
AI
